BiotechTube
REMD Biotherapeutics

REMD Biotherapeutics

San Diego, United States· Est.
remdbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $110M

Overview

REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.

Metabolic DiseasesOncologyCardiovascular

Technology Platform

Expertise in developing therapeutic antibodies against G Protein-Coupled Receptors (GPCRs). Platforms for generating bispecific antibodies including SynermAb and Tumor Activated Interferon (TAI) platforms.

Funding History

2
Total raised:$110M
Series B$70M
Series A$40M

Opportunities

Volagidemab's unique mechanism offers a differentiated approach in large diabetes and obesity markets, with potential for muscle-sparing weight loss.
Its development in oncology-supportive care (PI3Ki hyperglycemia) addresses a growing niche.
The bispecific platforms present opportunities in the high-value immuno-oncology space through partnerships and internal programs.

Risk Factors

High clinical development risk as lead asset advances to Phase 3.
Intense competition in core metabolic markets from large pharma.
Financial risk as a private, pre-revenue company needing significant capital for late-stage trials.
Execution risk managing operations and partnerships across the U.S.
and China.

Competitive Landscape

In diabetes/obesity, REMD competes with giants like Novo Nordisk, Eli Lilly, and others dominating the GLP-1/GIP market. Its GCGR antagonist is a niche mechanism, competing with other approaches like amylin analogs and SGLT2 inhibitors. In bispecifics, it faces numerous biotechs and pharma companies with advanced platforms. Its differentiation lies in its specific GPCR expertise and conditionally active bispecific designs.

More companies in Biologics / Biosimilars →More companies in United States →